Secondary hyperparathyroidism (2HPT), a common disorder in patients with chronic renal failure, develops in response to phosphate retention and low serum 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol). Replacement therapy with calcitriol or its precursor 1a-hydroxyvitamin D 3 (1aOHD 3 , alfacalcidol) often produces hypercalcaemia, especially when combined with calcium-based phosphate binders. In addition, these vitamin D compounds can aggravate the hyperphosphataemia in these patients. Several vitamin D analogues have been developed that retain the direct suppressive action of 1,25(OH) 2 D 3 on the parathyroid glands but have less calcaemic activity, thereby offering a safer and more effective means of controlling 2HPT. 1,25-Dihydroxy-19-norvitamin D 2 (19-norD 2 ) and 1a-hydroxyvitamin D 2 (1aOHD 2 ) are available in the US and 1,25-dihydroxy-22-oxavitamin D 3 (22-oxacalcitriol, OCT) and 1, 25-dihydroxy-26,26,26, 27,27,27-hexafluorovitamin D 3 (1,25(OH) 2 26,27F6 D 3 , falecalcitriol) have been approved for use in Japan. Animal studies have demonstrated that OCT and 19-norD 2 have a wider therapeutic window for suppression of parathyroid hormone (PTH) because of their lower calcaemic and phosphataemic activities. The low calcaemic activity of OCT has been attributed to its rapid clearance, which prevents sustained effects on intestinal calcium absorption and bone resorption, but still allows a prolonged suppression of PTH gene expression and parathyroid cell growth. The calcaemic activity of 19-norD 2 diminishes with the duration of treatment by as yet unknown mechanisms. The lower toxicity of 1aOHD 2 , compared with 1aOHD 3 , has also been noted with chronic, but not acute administration, perhaps due to differential metabolism. The unique actions of falecalcitriol may also result from an altered metabolism. A clear understanding of the molecular basis for the selectivity of vitamin D analogues on parathyroid function may allow the design of even more effective analogues.
Introduction
Secondary hyperparathyroidism (2HPT) is a common complication in patients with chronic renal failure. The pathogenesis of this disorder, characterized by increased parathyroid hormone (PTH) secretion and parathyroid gland hyperplasia, is attributed primarily to the retention of phosphate and the decreased capacity to produce 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 , calcitriol). These two factors influence parathyroid gland function by both direct and indirect means. Low serum 1,25(OH) 2 D 3 reduces intestinal calcium transport and bone calcium mobilization, and high serum phosphate further contributes to the hypocalcaemia by decreasing the free serum calcium. The parathyroid glands respond initially to the low calcium by increasing PTH secretion and synthesis, but prolonged hypocalcaemia leads to parathyroid gland hyperplasia. Hyperphosphataemia can directly (independently of changes in calcium or 1,25(OH) 2 D 3 ) increase PTH synthesis, stabilize PTH mRNA, promote parathyroid hyperplasia, and decrease the calcium receptor. The fall in serum 1,25(OH) 2 D 3 reduces the direct suppressive effects of this hormone on PTH gene transcription and parathyroid cell hyperplasia and may contribute to the reduced levels of receptors for calcium and vitamin D.
Prevention and treatment of 2HPT requires both the control of serum phosphate and the restoration of 1,25(OH) 2 D 3 levels. Phosphate is commonly controlled by reducing dietary phosphate absorption, usually by oral administration of calcium-based phosphate binders. Replacement therapy with 1,25(OH) 2 D 3 or its precursor 1aOHD 3 has been used with success, but is often precluded by the narrow therapeutic window for suppression of PTH without hypercalcaemia, especially when combined with oral calcium. For these reasons, analogues of vitamin D that retain the direct suppressive effect of 1,25(OH) 2 D 3 on the parathyroid glands but that have lower calcaemic and phosphataemic activity could provide a safer and more effective means of controlling 2HPT.
Development of vitamin D analogues for 2HPT
The initial selection criteria for vitamin D analogues for 2HPT were: (i) the retention of vitamin D receptor (VDR) affinity and the ability to suppress PTH synthesis and secretion in vitro and (ii) to display reduced calcaemic and phosphataemic activity in vivo. Those meeting these requirements were then tested in animal models of renal failure for their therapeutic windows for inhibition of PTH without hypercalcaemia. The following section discusses vitamin D analogues proven effective in both experimental animal models anduor clinical trials. Four of these compounds are now approved for use in patients with 2HPT in renal failure, and others are currently under development.
1,25-Dihydroxy-22-oxavitamin D 3 (22-oxacalcitriol, OCT) 22-oxacalcitriol, OCT, developed by Chugai Pharmaceutical Co., Ltd in Japan was the first analogue shown to exert a selective action on the parathyroid glands. The substitution of an oxygen in place of carbon 22 in the side chain (Figure 1 ) is the only difference between OCT and 1,25(OH) 2 D 3 . Despite its very low calcaemic activity in experimental animals, OCT was more potent than 1,25(OH) 2 D 3 in arresting cell growth and inducing differentiation in leukaemia cells (HL-60) in vitro [1] . In addition, OCT mimicked 1,25(OH) 2 D 3 in the suppression of PTH secretion in vitro in cultures of bovine parathyroid cells [2] . Similar to 1,25(OH) 2 D 3 , OCT suppression of PTH also involved reduction in PTH mRNA in normal rats [2] , suggesting control by transcriptional repression of the PTH gene.
The greater therapeutic index of OCT in suppressing PTH was demonstrated in animal models of renal failure. In contrast to the significant increase in serum calcium produced by doses of 1,25(OH) 2 D 3 just above those that suppress PTH (Figure 2 ), OCT was able to suppress PTH over a wide dose range with no change in serum calcium. Naveh-Many and Silver [3] found that OCT was slightly less active than 1,25(OH) 2 An important property of OCT is its ability to elicit a prolonged suppression of PTH. In uraemic rats, a single injection of 40 ng of OCT reduced PTH mRNA levels for 48 h [2] . Similarly, a single injection of a noncalcaemic dose of OCT to uraemic dogs was shown to suppress serum PTH for up to 69 h [4] . This prolonged suppression of PTH is a critical feature for the selectivity of OCT as discussed below in the section on mechanisms.
The suppression of PTH by OCT leads to amelioration of PTH-induced, high-turnover bone disease in experimental animal models and in patients with advanced renal failure. In a rat model of osteitis fibrosa, OCT lowered serum PTH and decreased the rates of both bone formation and resorption, and reduced the fibrosis volume of the bone without signs of hypercalcaemia or adynamic bone disease [5] . Treatment of renal osteodystrophy in uraemic dogs, with doses of OCT adjusted to maximize PTH suppression but to avoid hypercalcaemia, resulted in no change in the rate of bone turnover. However, the analogue reversed abnormalities in bone formation, including woven osteoid and fibrosis. In addition, although hypercalcaemic episodes occurred in the 60 weeks of OCT administration, the analogue did not induce lowturnover bone disease [6] . In a small group of patients with severe 2HPT, after 24 weeks of treatment, OCT significantly reduced bone marrow fibrosis, and decreased markers of bone turnover, although significant decreases were seen only in osteoid volume and bone formation rate [7] .
Given the efficacy of OCT to suppress PTH and correct the high-turnover bone disease but with lower calcaemic activity, this analogue should provide a safer means of treating renal failure patients. The results of the clinical studies with OCT are detailed by Kinugasa and by Akizawa in later articles in this issue. In Japan, OCT (generic name maxacalcitol) was approved for the treatment of 2HPT in patients in 2000, and is marketed under the name Oxarol 1 . [8] .
In uraemic rats, 19-norD 2 not only effectively suppressed PTH over a wide dose range without inducing hypercalcaemia but was less phosphataemic as well [8] (Figure 2) . Analysis of the parathyroid glands of uraemic rats treated with 19-norD 2 showed that it decreased PTH mRNA, suggesting that the analogue suppressed PTH via the same transcriptional repression mechanism as 1,25(OH) 2 D 3 .
It was recently shown that treatment with 19-norD 2 could both prevent and arrest the development of highturnover bone disease in uraemic rats. Slatopolsky et al. [9] reported that prophylactic treatment of uraemic rats with 19-norD 2 for the first 2 months following partial nephrectomy largely prevented increases in bone formation rate, unmineralized osteoid, bone resorption, and fibrosis. Of greater clinical relevance, these investigators found that 19-norD 2 could reverse the abnormal bone metabolism in rats with chronic renal failure and established parathyroid bone disease [9] . Therefore, PTH-induced high-turnover bone disease can be prevented and reversed by the ability of 19-norD 2 to correct serum PTH levels.
Although calcitriol treatment has been shown to block parathyroid hyperplasia in uraemic rats [10] , this effect could have been attributed to the mild hypercalcaemia seen at the doses used. Takahashi et al. [11] found that non-calcaemic doses of 19-norD 2 , when administered from the time of induction of renal failure, reduced the rate of parathyroid gland growth in uraemic rats, suggesting that it may have the ability to arrest parathyroid hyperplasia in patients. The mechanism for the antiproliferative effect of 19-norD 2 and calcitriol in the parathyroid is under investigation. Cozzolino et al. [12] reported that both 19-norD 2 and calcitriol, as well as high calcium and low phosphate, suppressed the expression of transforming growth factor alpha and induced the cell cycle inhibitor p21 in the parathyroid glands of uraemic rats.
The success of the pre-clinical studies led to trials in renal failure patients. The largest clinical experience with vitamin D analogues in renal failure patients has been using 19-norD 2 . Martin et al. [13] reported the results of a multicentre trial in which 19-norD 2 was compared with placebo. After a 4-week washout period, 19-norD 2 or placebo was administered three times per week after dialysis for 12 weeks. The dose of 19-norD 2 was started at 0.04 mgukg and increased by 0.04 mgukg every 2 weeks until a target PTH reduction of 30% was achieved. Of the patients receiving 19-norD 2 , 27 out of 40 had at least a 30% decrease in intact PTH, compared with three of 38 patients receiving placebo. There was no increase in serum calcium or phosphate before reaching this designated goal. Out of 414 determinations of serum calcium in the 19-norD 2 -treated group, only eight exceeded 11 mgudl compared with four in the placebo group. Only calcium-based phosphate binders were used in this study. Alkaline phosphatase improved only after 19-norD 2 treatment, evidence for a reduction of bone turnover. These findings demonstrated the efficacy and safety of 19-norD 2 in the treatment of 2HPT.
Martin et al. [14] reviewed the results from 78 patients treated in double blind placebo-controlled trials with 19-norD 2 . They noted that the PTH was suppressed by approximately 50% while serum calcium rose only 0.3"0.15 mgudl. Hypercalcaemic episodes uniformly occurred in patients with profound reductions or oversuppression of PTH.
Llach and Yudd [15] recently reported the results of an open-label study in patients who developed moderate to severe 2HPT despite treatment with calcitriol. All had experienced hypercalcaemia, hyperphosphataemia, or both during the previous 6 months of calcitriol therapy. After being switched to 19-norD 2 , mean PTH fell from 901 to 165 pguml at 16 months with no significant change in serum calcium or phosphate. Hypercalcaemic episodes occurred in eight patients but only when the PTH was less than 200 pguml. However, six patients had recurrent hyperphosphataemia. Thus, 19-norD 2 appeared to give better PTH suppression with a lower incidence of adverse outcomes.
Studies by Martin and collaborators [14] examined the dose equivalency of 19-norD 2 and 1,25(OH) 2 D 3 and found that a 4-fold higher dose of 19-norD 2 maintained PTH levels at their suppressed levels with no significant difference between the pre-and postcrossover levels. More recently, they have suggested that the initial dose of 19-norD 2 should be based on pre-treatment PTH levels, division of the serum PTH value (in pguml) by 80 is used to determine the microgram dose of 19-norD 2 to be given each dialysis session [16] .
These clinical trials demonstrated that 19-norD 2 is safe and effective in reducing PTH levels, and may cause less hyperphosphataemia and hypercalcaemia than calcitriol. This analogue, generic name paricalcitol, under the name Zemplar 1 , was approved for treatment of 2HPT in renal failure patients in the US in 1998.
1a-Hydroxyvitamin D 2 (1aOHD 2 )
A second vitamin D analogue, 1a-hydroxyvitamin D 2 (1aOHD 2 ), has become available for treatment of 2HPT in renal failure patients in the US (Figure 1 ). This compound, developed by Bone Care International, is a prodrug and, like its vitamin D 3 counterpart 1a-hydroxyvitamin D 3 (1aOHD 3 , alfacalcidol), must be activated in vivo. 1aOHD 2 was tested directly in dialysis patients; studies in experimental animal models of renal failure have not been reported. The results of a trial in renal failure patients with moderate to severe 2HPT (intact PTH greater than 400 pguml) were reported by Tan et al. [17] . After an 8-week washout period, oral 1aOHD 2 was administered initially at a dose of 4 mguday or 4 mg thrice weekly, and the dose was adjusted to maintain serum intact PTH levels between 130 and 250 pguml. The target goal was reached by 21 of the 24 patients. Mean serum calcium rose from 8.8 to 9.5 mgudl during the 12-week study, but average phosphate levels did not change. There were 13 episodes of hypercalcaemia (Ca greater than 10.5 mgudl) in 10 patients, and for the group, there were 4.7 hypercalcaemic episodes per 100 weeks of treatment vs 0.53 episodes per 100 weeks during the washout period. There were 30 episodes of hyperphosphataemia (P greater than 6.9 mgudl) in 18 patients during treatment vs 13 episodes in six patients during the washout; the rates of hyperphosphataemic episodes, 6.9u100 weeks during the washout vs 10.1u100 weeks during treatment, were not significantly different. There was no alteration of phosphate binders during the treatment phase.
A comparison of daily oral vs intermittent oral 1aOHD 2 by Frazao et al. [18] revealed comparable efficacies of daily and thrice-weekly dosages. The incidences of hypercalcaemia and hyperphosphataemia were very low in this small group of patients. A larger study was performed with 99 patients receiving calciumbased phosphate binders that consisted of an 8-week washout period, 16 weeks of open-label treatment with oral 1aOHD 2 and 8 weeks of double-blind crossover to either placebo or continued 1aOHD 2 [19] . Dosage was initiated at 10 mg 1aOHD 2 orally three times per week after each dialysis and adjusted to maintain PTH between 150 and 300 pguml while avoiding hypercalcaemia or hyperphosphataemia. PTH levels fell rapidly (by 35%) within 2 weeks and more slowly throughout the 16-week open-label treatment to a nadir of 44.7% of the baseline level. The target PTH range was achieved in 82 of the 99 patients. There were modest increases in serum calcium (q0.7 mgudl) and phosphate (q0.8 mgudl) in the open-label period. Hypercalcaemia (Ca greater than 10.5 mgudl) was detected in 15.3% of the measurements during the treatment period compared with 3.6% during the washout. The prevalence of hyperphosphataemia (P greater than 6.9 mgudl) was 18.9 and 6.6% in the treatment and washout periods, respectively. Oral 1aOHD 2 was judged to be safe and effective in treating 2HPT and was approved for use in patients in the US in 1999.
Intravenous (i.v.) 1aOHD 2 has also been introduced. Maung et al. [20] entered patients from the intermittent oral study described above [19] into a trial to compare the efficacy of i.v. 1aOHD 2 . Following an 8-week washout, 38 patients were given placebo and 32 patients were treated with i.v. 1aOHD 2 for 12 weeks. The initial i.v. dose was 4 mg three times per week after dialysis, compared with the 10 mg dose of oral 1aOHD 2 in the previous study, due to the 2.5 times higher bioavailability of the i.v. 1aOHD 2 . PTH levels decreased progressively during 12 weeks of i.v. 1aOHD 2 as it had with oral 1aOHD 2 . Comparison of the PTH levels during the i.v. trial and the first 12 weeks of the oral trial revealed similar rates of decrease. Serum calcium and phosphate levels rose slightly with i.v. 1aOHD 2 administration, but both the absolute and per cent increases were lower than with oral 1aOHD 2 . Incidents of hypercalcaemia and hyperphosphataemia were also lower with i.v. 1aOHD 2 . Thus, it appears that i.v. administration of 1aOHD 2 may be safer than the oral formulation. I.v. 1aOHD 2 (generic name doxercalciferol) is now available for use in patients under the brand name Hectorol 1 . 2 DHT may be another useful analogue for the treatment of 2HPT. Also under investigation are analogues with inverted stereochemistry at carbon 20, which have been demonstrated to be more potent than the natural diastereomers in various in vitro biological assays. Three of these analogues (CB 1093, EB 1213, and GS 1725) were tested in the uraemic rat model by Hruby et al. [24] . Following five daily injections of 250 ngukg, CB 1093 suppressed PTH by 73% with no increase in serum calcium and with a slight decrease in serum phosphate (3.72"0.65 to 2.95"0.98 mM). In contrast, the same dose of 1,25(OH) 2 D 3 reduced PTH by 82%, but part of this decrease could be attributed to the large increase in ionized calcium (1.17"0.04 to 1.55"0.14 mM) produced by this excessively high dose of 1,25(OH) 2 D 3 . EB 1213 at a dose of 1250 ngukguday lowered PTH by 61% with no change in ionized calcium, and GS 1725 at a much lower dose of 25 ngukguday suppressed PTH by 80% with only a slight, but not significant, increase in ionized calcium.
Clearly, there are many promising new analogues in development for the treatment of 2HPT.
Mechanisms for the selectivity of vitamin D analogues
To date, the analogues developed for 2HPT are considerably less calcaemic than 1,25(OH) 2 D 3 , but are slightly less active in suppressing PTH. The molecular basis for this selectivity is currently under investigation. Essentially, it is important to note that vitamin D compounds interact with only a few proteins in vivo. In general, the biological profile of vitamin D compounds will be determined by their interaction with four proteins or classes of proteins: (i) VDR that mediates the genomic actions; (ii) the serum vitamin D binding protein (DBP) and perhaps lipoproteins that transport vitamin D compounds and control their access to the target cell; (iii) the vitamin D 24-hydroxylase and perhaps other minor enzymes that metabolize anduor deactivates the analogues; and (iv) cell surface receptors that mediate the rapid, nongenomic actions of vitamin D compounds (Figure 3 ). Based on these protein interactions, a plausible explanation for the selectivity of OCT has been proposed. However, the mechanisms responsible for the distinctive actions of 19-norD 2 and 1aOHD 2 are not as clear.
OCT
The basis for the selectivity of OCT is probably the best understood of the new, less calcaemic vitamin D analogues. Its affinity for the VDR is about eight times lower than that of 1,25(OH) 2 D 3 , consistent with its slightly lower activity in suppressing PTH. However, its diminished affinity for DBP (approximately 500 times less than that of 1,25(OH) 2 D 3 ) is what accounts for its very low calcaemic activity [25] [26] [27] . DBP affinity is a major determinant of the pharmacokinetics of vitamin D compounds. Studies in rats and dogs demonstrated that OCT is rapidly cleared from the circulation and achieves lower maximal levels (C max ) in the blood when administered intraperitoneally [25, 27, 28] . Despite the lower C max , the amount of OCT associated with the intestinal VDR [27] and parathyroid glands [28] at early times post-injection were higher than those of 1,25(OH) 2 D 3 , but fell rapidly after the analogue was cleared from the circulation. This 'pulse' of OCT into its target tissues elicited only transient increases in intestinal calcium transport and bone mobilization, while the effects of 1,25(OH) 2 D 3 were much more prolonged [27] .
It is probable that pharmacokinetics are responsible for the short-lived effects of OCT on the intestine and bone. Infusion of OCT by osmotic minipumps for 3 days led to a sustained increase in intestinal calcium transport similar to that achieved by infusion of 1,25(OH) 2 D 3 . When the pumps were removed, intestinal calcium transport returned to basal rates in the OCT-infused rats within 24 h, but remained elevated in the 1,25(OH) 2 D 3 -infused rats [27] . In addition, Sato et al. [29] found that OCT was equipotent to 1,25(OH) 2 D 3 in stimulating bone resorption in organ culture where pharmacokinetics cannot influence the results.
In contrast to the transient effects of OCT on the intestine and bone, this analogue elicits a prolonged suppression on PTH gene expression. Studies reported by Brown et al. [4] demonstrated that a single injection of OCT in uraemic dogs reduced serum PTH maximally for more than 48 h. Studies in normal rats confirmed that PTH mRNA levels were still suppressed 48 h after a single injection of a non-calcaemic dose of OCT reduced PTH mRNA [2] . The molecular basis for the differences in the durations of effects of OCT in the parathyroid gland vs those in the intestine and bone are unclear. However, an article by Koike and Stumpf later in this issue, demonstrates by microautography that OCT is retained in the nuclei of parathyroid cells for prolonged periods after injection and may be responsible for the sustained reduction of PTH. Thus, it appears that suppression of PTH is a long-lived response, whereas stimulation of intestinal calcium absorption and bone resorption are short-lived responses that require continuous exposure to the vitamin D analogue. OCT appears to exert its selectivity via its rapid clearance, which exploits the differences in the biological half-lives of the desirable (PTH suppression) and undesirable (increased calcium) responses (Figure 4) .
The unique biological actions of OCT may be attributed to other factors as well. Takeyama et al. OCT can also reduce endogenous 1,25(OH) 2 D 3 levels by inhibiting the renal 1a-hydroxylase and by inducing the catabolic enzyme 24 -hydroxylase [31, 32] . This may have an important influence on the biological actions of OCT. Effects of 1,25(OH) 2 D 3 that are not supported by OCT will be reduced due to the loss of endogenous 1,25(OH) 2 D 3 , leading to selective vitamin D deficiencies.
Cell-specific catabolism of OCT may also play a role in the selectivity of this analogue. OCT and 1,25(OH) 2 D 3 were found to be catabolized at equal rates in bovine parathyroid cells [33] . In contrast, OCT was degraded more slowly than 1,25(OH) 2 D 3 in human macrophages [34] , but more rapidly in keratinocytes [35] . Thus, differential rates of catabolism may also produce cell-specific effects of OCT. It is apparent that the distinct novel biological properties of OCT are determined by multiple mechanisms.
19-NorD 2
The mechanism of action of 19-norD 2 is less clear than that of OCT, although it appears not to involve pharmacokinetics. The VDR affinity of 19-norD 2 is about three times less than that of 1,25(OH) 2 D 3 , consistent with its slightly lower potency in suppressing PTH. Unlike OCT, 19-norD 2 has a relatively high DBP affinity, being only three time less than that of 1,25(OH) 2 D 3 [36] . Not surprisingly then, the clearance rates and tissue localization of 19-norD 2 and 1,25(OH) 2 D 3 are similar [36] . It is somewhat of a paradox that 19-norD 2 has a lower calcaemic activity than 1,25(OH) 2 D 3 when its VDR affinity and ability to localize to the bone and intestine are very similar to 1,25(OH) 2 D 3 . In fact, a single injection of 19-norD 2 produced the same dose-dependent increases in intestinal calcium transport and bone mobilization at 24 h as 1,25(OH) 2 D 3 [36] . A time course for the calcaemic effects of 19-norD 2 and 1,25(OH) 2 D 3 revealed similar increases in serum calcium after a single injection, but the time courses diverged with continued treatment ( Figure 5 ). After chronic (7 days) treatment, there were significant differences in the effects of 19-norD 2 and 1,25(OH) 2 D 3 on intestine calcium transport and bone mobilization [36] . This apparent loss of responsiveness to 19-norD 2 after 7 days of treatment could not be attributed to a change in its pharmacokinetics or to a reduction in intestinal VDR content.
Longer treatment periods with 19-norD 2 (2 months) in uraemic rats have been shown to lower the levels of intestinal VDR [11] . This was associated with a reduction in the endogenous levels of 1,25(OH) 2 D 3 . Thus, 19-norD 2 , like OCT, can lower serum 1,25(OH) 2 D 3 possibly leading to selective vitamin D deficiencies. In addition, the decrease in VDR content could also play a role in the lower calcaemic activity of 19-norD 2 with chronic administration.
Direct effects of 19-norD 2 on osteoclast maturation and osteoclastic bone mobilization were assessed in vitro using a mouse bone marrow culture system. In this model, vitamin D compounds can promote the differentiation of bone marrow osteoclast precursors into multinucleated cells that express tartrate-resistant acid phosphatase, and other markers of mature osteoclasts [37] , through induction of a receptor activator of NFkB ligand (RANKL) on the surface of osteoblasts. When the cultures containing the mature osteoclasts and osteoblasts are plated onto bone (or dentine) slices, vitamin D compounds, via continued induction of RANKL, can activate the osteoclasts to resorb the bone surface. In this model, 19-norD 2 was equipotent to 1,25(OH) 2 D 3 in promoting osteoclast maturation, but appeared to be less active in stimulating the osteoclasts to resorb bone [38] . Further analysis revealed that the number of osteoclasts attached to the bone slices and the area resorbed per pit were the same for 19-norD 2 and 1,25(OH) 2 D 3 , indicating that the reduced bone resorption in response to 19-norD 2 could be attributed to a defective initiation of resorption by the osteoclasts. The mechanism for this is still under investigation, but no difference in VDR content was detected and rates of catabolism of 19-norD 2 and 1,25(OH) 2 D 3 in these cultures were similar. Studies by Finch et al. [39] demonstrated that 19-norD 2 and 1,25(OH) 2 D 3 were equipotent in inducing differentiating and several markers of bone formation in the human osteoblastic cell line MG-63. It was proposed that the reduced effect of 19-norD 2 on bone resorption might be due to a reduced ability to specifically induce RANKL.
1aOHD 2
The mechanism for the reduced calcaemic activity of 1aOHD 2 is much less understood than for the other analogues. Early studies with 1aOHD 2 showed that it was less toxic than 1aOHD 3 when the compounds were administered chronically [40] , and this is the rationale for using 1aOHD 2 in place of 1aOHD 3 for treatment of 2HPT. The explanation for the lower calcaemic activity of 1aOHD 2 is unclear as this same study showed that stimulation of calcium transport and bone mobilization by 1aOHD 2 and 1aOHD 3 were not different [40] . Unlike the other vitamin D analogues, 1aOHD 2 is actually a pro-hormone that is activated under physiologic conditions mainly to 1,25(OH) 2 D 2 . Several studies have shown that 1,25(OH) 2 D 2 has the same potency as 1,25(OH) 2 D 3 in stimulating calcium transport in vivo and bone mobilization in vivo [41, 42] and in vitro [38] . Recently, however, Mawer et al. [43] demonstrated that vitamin D 2 , but not vitamin D 3 , could be converted to 1,24(OH) 2 D 2 , a metabolite with potent cell differentiation activity, but much lower calcaemic activity than 1,25(OH) 2 D 2 or 1,25(OH) 2 D 3 . It has been proposed that 1aOHD 2 , but not 1sOHD 3 , may be 24-hydroxylated within target cells to produce an active metabolite (1,24(OH) 2 D 2 ) that is less calcaemic and phosphataemic ( Figure 6 ).
Falecalcitriol
The distinct actions of falecalcitriol appear to involve altered pharmacokinetics. The fluorine atoms at the end of the side chain have been shown to impede catabolism of this molecule. Unlike 1,25(OH) 2 D 3 , which is hydroxylated at carbons 23 and 24 and then oxidatively cleaved to calcitroic acid, falecalcitriol is only partially metabolized, primarily to its 23-hydroxylated metabolite, 1,23,25-trihydroxy-26,26,26,27,27,27-hexafluorovitamin D 3 , in vivo [44, 45] and in various cell culture systems [46 -48] (Figure 7 ). This intermediate retains considerable biological activity. The fluorine atoms also reduce binding to DBP, and falecalcitriol is cleared slightly more rapidly than 1,25(OH) 2 D 3 [49] . Despite the shorter circulating half-life and 3-fold lower affinity for the VDR, falecalcitriol has prolonged and potent biological activity in vivo, presumably due to its slower target tissue metabolism. It is unclear if this produces a selective action on the parathyroid glands.
Future perspectives
The vitamin D analogues currently available can effectively suppress PTH in chronic renal failure patients with less calcaemic activity, thus offering safer alternatives to 1,25(OH) 2 D 3 in the treatment of 2HPT and renal osteodystrophy. A better understanding of how modifications of the vitamin D molecule can influence an analogue's interactions with the VDR, DBP, the 24-hydroxylase, and the membrane receptor should help in the design of new analogues with greater specificity and a larger margin of safety for treatment of 2HPT, renal osteodystrophy, as well as other diseases.
